FXYD5 and cancer: EDC1 is a non-internalizing extracellular drug conjugate composed of an anti-dysadherin antibody (NCC-M53) conjugated to CEN-106, a novel Na,K-ATPase inhibitor known to induce necrosis in human cancer cell types [33].